Carcinogenesis, Vol. 23, No. 10, 1721-1727,
October 2002
© 2002 Oxford University Press
CARCINOGENESIS |
4-Aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene
1 Department of Environmental Medicine,
2 Department of Medicine and
3 Department of Pathology, New York University School of Medicine, Tuxedo, NY 10987 and
4 Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA
4-Aminobiphenyl (4-ABP) is a major etiological agent of human bladder cancer, and its metabolites are able to form DNA adducts that may induce mutation and initiate bladder carcinogenesis. Thirty to sixty percent of human bladder cancer has a mutation in the p53 gene, and the mutational spectrum bears two characteristics: compared with other cancers, the pattern of mutations is more evenly distributed along the p53 gene, and the mutational hotspots occur at both CpG sites, such as codons 175, 248 and 273, and non-CpG sites, such as codons 280 and 285, the latter two being unique mutational hotspots for bladder and other urinary tract cancers. These findings raise the possibility that the special p53 mutational features in human bladder cancer are due to the unique binding spectrum of metabolically activated 4-ABP in bladder cells. To address this question, here we have mapped the 4-ABP–DNA adduct distribution in the p53 gene at the nucleotide sequence level in human bladder cells. We found that, unlike benzo[a]pyrene trans-7,8-dihydrodiol-9,10-epoxide–DNA adduction, which preferentially occurs at CpG sites, 4-ABP–DNA adduction is not biased for CpG sites, and the adducts are more evenly distributed along the p53 gene; nonetheless, the p53 mutational hotspots in bladder cancer at codons 175, 248, 280 and 285 are also the preferential sites for 4-ABP adduct formation. These results strongly suggest that the unique binding spectrum of 4-ABP contributes greatly to the unique mutational spectrum in the p53 gene of human bladder cancer, and provide further molecular evidence to directly link 4-ABP to bladder cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Saletta, G. Matullo, M. Manuguerra, S. Arena, A. Bardelli, and P. Vineis Exposure to the Tobacco Smoke Constituent 4-Aminobiphenyl Induces Chromosomal Instability in Human Cancer Cells Cancer Res., August 1, 2007; 67(15): 7088 - 7094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zayas, S. W. Stillwell, J. S. Wishnok, L. J. Trudel, P. Skipper, M. C. Yu, S. R. Tannenbaum, and G. N. Wogan Detection and quantification of 4-ABP adducts in DNA from bladder cancer patients Carcinogenesis, February 1, 2007; 28(2): 342 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Feng, W. Hu, Y. Hu, and M.-s. Tang From the Cover: Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair PNAS, October 17, 2006; 103(42): 15404 - 15409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Sugamori, D. Brenneman, and D. M. Grant In Vivo and in Vitro Metabolism of Arylamine Procarcinogens in Acetyltransferase-Deficient Mice Drug Metab. Dispos., October 1, 2006; 34(10): 1697 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Arakawa, F. Wu, M. Costa, W. Rom, and M.-s. Tang Sequence specificity of Cr(III)-DNA adduct formation in the p53 gene: NGG sequences are preferential adduct-forming sites Carcinogenesis, March 1, 2006; 27(3): 639 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.A. Crallan, N.T. Georgopoulos, and J. Southgate Experimental models of human bladder carcinogenesis Carcinogenesis, March 1, 2006; 27(3): 374 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lin, F. F. Kadlubar, M. R. Spitz, H. Zhao, and X. Wu A Modified Host Cell Reactivation Assay to Measure DNA Repair Capacity for Removing 4-Aminobiphenyl Adducts: A Pilot Study of Bladder Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1832 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wallerand, A. A. Bakkar, S. G. D. de Medina, J.-C. Pairon, Y.-C. Yang, D. Vordos, H. Bittard, S. Fauconnet, J.-C. Kouyoumdjian, M.-C. Jaurand, et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens Carcinogenesis, January 1, 2005; 26(1): 177 - 184. [Abstract] [Full Text] [PDF]
|
|